Professor Sian Harding is Professor of Cardiac Pharmacology at NHLI, Imperial College London; Head of the Division of Cardiovascular Sciences and Director of the Imperial British Heart Foundation Cardiovascular Regenerative Medicine Centre. Her work has centered on the myocardium in heart failure, especially beta-adrenergic mechanisms. She was PI on the first UK Gene therapy Trial in LVAD patients, aimed at improving cardiac contractility. She is now studying the pluripotent stem cell-derived cardiomyocyte, both for disease modelling and cardiac repair. Professor Harding is former President of the European Section of the International Society for Heart Research and member of the Nuffield Council on Bioethics. She has been elected Fellow of both the American Heart Association and the European Society of Cardiology, and is on the Board of the British Society of Gene and Cell Therapy.
